Alembic Pharmaceuticals gets final USFDA nod for hypertension drug

25 Apr 2017 Evaluate

Alembic Pharmaceuticals has received final approvals from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Applications (ANDAs) for Olmesartan Medoxomil Tablets, 5 mg, 20mg and 40mg and Olmesartan Medoxomil with Hydrochlorothiazide Tablets 20/12.5mg, 40/12.5mg and 40/25mg.

The approved ANDAs are therapeutically equivalent to the reference listed drug products (RLDs) Benicar Tablets 5mg, 20mg and 40mg and Benicar HCT Tablets, 20/12.5mg, 40/12.5mg and 40/25mg, of Daiichi Sankyo Inc. The approved ANDAs are indicated for the treatment of hypertension.

According to IMS, Benicar and Benicar HCT have an estimated market size of $1.8 billion for twelve months ending December 2016. Alembic now has a total of 55 ANDA approvals (49 final approvals and 6 tentative approvals) from the USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.


Alembic Pharma Share Price

763.30 -6.90 (-0.90%)
20-Jan-2026 14:25 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1615.00
Dr. Reddys Lab 1175.10
Cipla 1382.55
Zydus Lifesciences 874.20
Lupin 2171.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×